Xilio Therapeutics (XLO) Total Non-Current Liabilities (2020 - 2026)

Xilio Therapeutics has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $51.8 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 41.28% year-over-year to $51.8 million; the TTM figure through Jun 2026 stood at $51.8 million (down 41.28% YoY), while the FY2025 annual figure was $89.9 million, changed N/A from the prior year.
• Total Non-Current Liabilities came in at $51.8 million for Q2 2026 at Xilio Therapeutics, down from $64.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $89.9 million in Q4 2025 to a low of $25.0 million in Q2 2023.
• Average Total Non-Current Liabilities over 4 years is $51.1 million, with a median of $33.8 million recorded in 2022.
• Year-over-year, Total Non-Current Liabilities rose 2.95% in 2022 and slumped 41.28% in 2026.
• Over 4 years, Total Non-Current Liabilities stood at $33.5 million in 2022, then fell by 25.39% to $25.0 million in 2023, then soared by 259.77% to $89.9 million in 2025, then sank by 42.36% to $51.8 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $51.8 million in Q2 2026, $64.7 million in Q1 2026, and $89.9 million in Q4 2025.